Compare Prudential Financial Inc (PRU) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Prudential Financial Inc vs TransMedics Group Inc — how do they compare? Prudential Financial Inc trades at $112.98 (market cap $39.17B), while TransMedics Group Inc trades at $78.32 (market cap $2.74B). The key difference: Prudential Financial Inc is far larger — about 14.3× TransMedics Group Inc's market cap, and Prudential Financial Inc pays a 4.93% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Prudential Financial Inc for 145 Days and TransMedics Group Inc for 24 Days on average.
| PRU | TMDX | |
|---|---|---|
Market Cap | $39.17B | $2.74B |
Volume | 1,436,917 | 949,331 |
Sector | Financials | Health |
52-Week High | $125.13 | $150.42 |
52-Week Low | $92.00 | $61.99 |
Typical Hold Time | 145 Days | 24 Days |
Enterprise Value | $67.95B | $3.13B |
Dividend Yield | 4.93% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Prudential Financial (PRU) trades at $112.97, up 0.54% with a bearish technical signal despite recent earnings beats. The stock shows attractive valuation metrics with P/E of 10.29 and P/S of 0.61, while maintaining solid profitability with 6.04% net margin and 12.46% ROE. Recent strategic moves include the Alexforbes stake sale and rebranding to Prudential Wealth Advisors, reflecting focus on core operations.
While PRU offers value appeal through strong fundamentals and dividend yield, investors face headwinds from bearish technicals and mixed analyst sentiment. The company's capital rotation strategy and PGIM growth initiatives provide upside potential, but execution risks and market volatility remain concerns. Current price sits above consensus target of $105.67, suggesting limited near-term upside.
TransMedics Group (TMDX) trades at $78.17, down 3.58% on the day, with a bearish technical signal and mixed earnings history. The company reported strong 2025 results with $605.49M revenue and $190.29M net income, but 2026 projections show margin compression. Recent news highlights insider buying and leadership changes alongside legal investigations into fiduciary duties, creating a complex sentiment backdrop.
The stock offers growth potential with a consensus price target of $99.75, but faces risks from earnings misses, margin pressure, and ongoing legal scrutiny. Analyst consensus remains bullish with 69% buy ratings, yet investors must weigh robust profitability metrics against execution and regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Prudential Financial Inc
Prudential Financial is a large, diversified insurance company offering annuities, life insurance, retirement plan services, and asset management products. While it operates in a number of countries, the vast majority of revenue is generated in the United States and Japan. The company's investment management business, PGIM, contributes approximately 15% of its earnings and has over $1.5 trillion in assets under management. The U.S. businesses are responsible for about 45% of earnings and can be classified into Institutional Retirement Strategies, Individual Retirement Strategies, Group Insurance, Individual Life Insurance, and Assurance IQ. Finally, the international business segment of the company contributes approximately 40% of earnings with a strong market position in Japan.
Read more on PRU →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
